Prothena Corporation plc (PRTA) Stock Forecast
PRTA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.71 / 5 from 7 analysts
- Price target
- $21.40 average of analyst targets
- Upside to target
- +156.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.38
- 52-week range
- $7.91 – $11.51
PRTA analyst ratings
7 analystsNumber of analysts at each rating.
PRTA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRTA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.38 | −$0.22 | −$0.67 | +55.2% | 2 |
| Current fiscal year (2026) | $0.64 | $0.64 | $0.64 | −$3.98 | +116.1% | 1 |
| Next fiscal year (2027) | −$1.31 | −$1.52 | −$1.11 | $0.64 | −305.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRTA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $8.2M | $0 | $55.0M | +239.9% | 7 |
| Current fiscal year (2026) | $82.7M | $52.1M | $107.1M | +754.0% | 7 |
| Next fiscal year (2027) | $21.0M | $0 | $100.0M | −74.6% | 7 |
PRTA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRTA revenue: reported and forecast
PRTA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.38 | −$0.38 | −$0.38 | −$0.30 | −20.0% | 1 up · 0 down |
| Current fiscal year (2026) | $0.05 | $0.00 | $0.00 | $0.00 | $0.64 | +1,180.0% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.31 | −$1.52 | −$1.52 | −$1.52 | −$1.31 | +0.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRTA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRTA beat in 7 of 12.
What analysts expect from PRTA
7 analysts cover Prothena; their consensus rating is buy (3.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.40, 156.3% above the latest close of $8.35. Analysts expect earnings of $0.64 per share for 2026, +116.1% from a year earlier. For 2027 the average estimate is −$1.31 per share on revenue of $21.0 million. Prothena beat the EPS estimate in 7 of the last 12 quarters.
Related: PRTA income statement, PRTA key metrics, PRTA chart. See the PRTA stock overview for the latest quote and news.
PRTA forecast FAQ
What is Prothena's price target?
The average analyst price target for Prothena is $21.40, 156.3% above the latest close of $8.35.
Is Prothena a buy, hold or sell?
Of 7 analysts covering Prothena, 2 rate it a strong buy, 2 a buy, 2 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Prothena's EPS forecast?
Analysts forecast $0.64 per share for 2026 (range $0.64 to $0.64); for 2027 the estimate is −$1.31.
What is Prothena's revenue forecast?
The average revenue estimate for 2026 is $82.7 million, growth of 754.0%; for 2027 it is $21.0 million.
When does Prothena report earnings?
Prothena is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.38.
Does Prothena usually beat earnings estimates?
Prothena reported EPS at or above the analyst estimate in 7 of the last 12 quarters.